Claire E. Thomas

Claire E. Thomas

Auto-generated profile, based on publicly available information

Claire E. Thomas

Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
CTClaire E. Thomas
Claire E. Thomas
RWRenwei Wang
Renwei Wang
JAJennifer Adams-Haduch
Jennifer Adams-Haduch
SMSharon E. Murphy
Sharon E. Murphy
PUPer Magne Ueland
Per Magne Ueland
Jian-Min YuanJian-Min Yuan
Jian-Min Yuan
Background: Cotinine is a metabolite of nicotine. Serum and urinary cotinine are validated biomarkers for cigarette exposure. Their performance for lung cancer risk prediction has not been simultaneously examined in epidemiologic studies. Methods: A nested case–control study, including 452 incident lung cancer cases and 452 smoking-matched controls in the Shanghai cohort study, was conducted. Mass spectrometry–based methods were used to quantify cotinine in serum and urine samples collected from current smokers at baseline, on average 10 years before cancer diagnosis of cases. Logistic regression was used to estimate ORs, 95% confidence intervals (CI), and AUC ROC for lung cancer associated with higher levels of cotinine. Results: Serum and urinary cotinine levels were significantly higher in lung cancer cases than controls. Compared with the lowest quartile serum cotinine (≤0.40 nmol/mL), the OR of lung cancer for smokers in the highest quartiles (>1.39 nmol/mL) was 5.46 (95% CI, 3.38–8.81). Similarly, the OR was 5.49 (95% CI, 3.39–8.87) for highest (>16.38 nmol/mg creatinine) relative to the lowest quartile of urinary total cotinine (≤4.11 nmol/mg creatinine). A risk prediction model yielded an AUC of 0.72 (95% CI, 0.69–0.75) for serum cotinine and 0.72 (95% CI, 0.69–0.75) for urinary total cotinine combined with smoking history. Conclusions: Urinary and serum cotinine have the same performance in prediction of lung cancer risk for current smokers. Impact: Urinary cotinine is a noninvasive biomarker that can replace serum cotinine in risk prediction of future lung cancer risk for current smokers.

14 October 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
YYYi-Chuan Yu
Yi-Chuan Yu
HLHUNG LUU
HUNG LUU
RWRenwei Wang
Renwei Wang
CTClaire E. Thomas
Claire E. Thomas
Nancy W GlynnNancy W Glynn
Nancy W Glynn
Jian-Min YuanJian-Min Yuan
Jian-Min Yuan
Background: Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epidemiologic data on iron overload without hemochromatosis in relation to HCC are sparse. This study aimed to examine the associations between serum biomarkers of iron and the risk of HCC in patients with NAFLD. Methods: We identified 18,569 patients with NAFLD using the University of Pittsburgh Medical Center electronic health records from 2004 through 2018. After an average 4.34 years of follow-up, 244 patients developed HCC. Cox proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of HCC incidence associated with elevated levels of iron biomarkers with adjustment for age, sex, race, body mass index, history of diabetes, and tobacco smoking. Results: The HRs (95% CIs) of HCC for clinically defined elevation of serum iron and transferrin saturation were 2.91 (1.34–6.30) and 2.02 (1.22–3.32), respectively, compared with their respective normal range. No statistically significant association was observed for total iron-binding capacity or serum ferritin with HCC risk. Conclusions: Elevated levels of serum iron and transferrin saturation were significantly associated with increased risk of HCC among patients with NAFLD without hemochromatosis or other major underlying causes of chronic liver diseases. Impact: Clinical surveillance of serum iron level may be a potential strategy to identify patients with NAFLD who are at high risk for HCC.

3 May 2022 in Hepatology Communications
Verified
Journal Article
Open access
CTClaire E. Thomas
Claire E. Thomas
BDBrenda Diergaarde
Brenda Diergaarde
AKAllison L Kuipers
Allison L Kuipers
JAJennifer J. Adibi
Jennifer J. Adibi
HLHUNG LUU
HUNG LUU
Jian-Min YuanJian-Min Yuan
Jian-Min Yuan
It is difficult to identify people with nonalcoholic fatty liver disease (NAFLD) who are at high risk for developing hepatocellular carcinoma (HCC). A polygenic risk score (PRS) for hepatic fat (HFC‐PRS) derived from non‐Asians has been reported to be associated with HCC risk in European populations. However, population‐level data of this risk in Asian populations are lacking. Utilizing resources from 24,333 participants of the Singapore Chinese Health Study (SCHS), we examined the relationship between the HFC‐PRS and HCC risk. In addition, we constructed and evaluated a NAFLD‐related PRS (NAFLD‐PRS) with HCC risk in the SCHS. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of HCC incidence with both HFC‐PRS and NAFLD‐PRS. The HFC‐PRS and NAFLD‐PRS were highly correlated (Spearman r = 0.79, p < 0.001). The highest quartiles of both the HFC‐PRS and the NAFLD‐PRS were associated with significantly increased risk of HCC with HR of 2.39 (95% CI 1.51, 3.78) and 1.77 (95% CI 1.15, 2.73), respectively, compared with their respective lowest quartile. Conclusion: The PRS for hepatic fat content or NAFLD may be useful for assessing HCC risk in both Asian and European populations. The findings of this and prior studies support a potential causal role of genetically determined NAFLD in HCC development.

28 November 2024 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
CTClaire E. Thomas
Claire E. Thomas
UPUlrike Peters
Ulrike Peters

13 November 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
HLHUNG LUU
HUNG LUU
JBJaideep Behari
Jaideep Behari
GGGeorge Boon-Bee Goh
George Boon-Bee Goh
RWRenwei Wang
Renwei Wang
AJAizhen Jin
Aizhen Jin
Jian-Min YuanJian-Min Yuan
Jian-Min Yuan
Background: While the associations between individual lifestyle factors and risk of hepatocellular carcinoma (HCC) have been described previously, their combined impact on HCC risk is unknown. Methods: The association of a composite score of healthy lifestyle factors, including body mass index, alcohol consumption, cigarette smoking, alternative Mediterranean diet, and sleep duration, and HCC risk was examined in the Singapore Chinese Health Study, an ongoing prospective cohort study of 63,257 Chinese men and women. Cox proportional hazard regression method was used to estimate HR and its 95% confidence interval (CI). Conditional logistic regression method was used to evaluate this composite lifestyle score–HCC risk association among a subset of individuals who tested negative for hepatitis B surface antigen (HBsAg) and anti–hepatitis C antibody. Results: After a mean follow-up of 17.7 years, 561 participants developed HCC. Individuals with higher composite scores representing healthier lifestyles (range 0–8) were at significantly lower risk of HCC. Compared with the lowest composite score category (0–4), the HRs (95% CIs) for the composite scores of 5, 6, 7, and 8 were 0.67 (0.62–0.85), 0.61 (0.48–0.77), 0.49 (0.37–0.65), and 0.13 (0.06–0.30), respectively (Ptrend < 0.0001). A similar inverse association was observed in participants with negative HBsAg and anti–hepatitis C virus (HCV)-negative serology (HR, 0.38; 95% CI, 0.19–0.79; for the highest vs. the lowest category of the composite scores; Ptrend = 0.001). Conclusions: Healthy lifestyles protect against HCC development, especially for individuals without hepatitis B virus and HCV infections. Impact: This study highlights the importance of a comprehensive lifestyle modification strategy for HCC primary prevention.

13 April 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
CTClaire E. Thomas
Claire E. Thomas
HLHUNG LUU
HUNG LUU
RWRenwei Wang
Renwei Wang
JAJennifer Adams-Haduch
Jennifer Adams-Haduch
AJAizhen Jin
Aizhen Jin
JYJian-Min Yuan
Jian-Min Yuan
Background: Intake of tomato and/or lycopene has been associated with reduced risk of several cancers, but there is no report on the association with risk of hepatocellular carcinoma (HCC). Methods: The associations of tomato and lycopene consumption with risk of HCC were examined in the Singapore Chinese Health Study, a prospective cohort of 63,257 Chinese ages 45 to 74 years at enrollment. Diet was assessed using a validated semiquantitative food frequency questionnaire. Cox proportional hazard regression models were used to estimate HR and its 95% confidence interval (CI) of HCC with the consumption of tomato and lycopene among all cohort participants, and unconditional logistic regression was used to assess the association by hepatitis B surface antigen (HBsAg) positivity in a nested case–control study. Results: After a mean follow-up of 17.6 years, 561 incident HCC cases were identified. Higher tomato intake was associated with lower risk of HCC after adjustment for potential confounders (Ptrend < 0.001). Compared with the lowest quartile, HRs (95% CIs) of HCC for the second, third, and fourth quartile of tomato intake were 0.70 (0.56–0.88), 0.73 (0.58–0.92), and 0.63 (0.49–0.81). Among HBsAg-negative individuals, the inverse association remained (Ptrend = 0.03). There was no association between lycopene intake and HCC risk (Ptrend = 0.54). Conclusions: Tomato intake may offer protection against the development of HCC, particularly among individuals without chronic infection with hepatitis B virus. Impact: Tomato intake is a low-cost preventative measure against HCC that may help reduce risk due to increasing rates of nonalcoholic fatty liver disease.